Journal of
Antimicrobial
Chemotherapy

# A whole-genome screen identifies *Salmonella enterica* serovar Typhi genes involved in fluoroquinolone susceptibility

A. Keith Turner [ID] [1]*†, Sabine E. Eckert[1], Daniel J. Turner[1]‡, Muhammud Yasir[2], Mark A. Webber [ID] [2,3],
Ian G. Charles[2,3], Julian Parkhill[1]§ and John Wain[3]†

[1]Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK; [2]Quadram Institute, Norwich
Research Park, Colney, Norwich NR4 7UA, UK; [3]University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK

*Corresponding author. E-mail: keith.turner@quadram.ac.uk
†Present address: Quadram Institute, Norwich Research Park, Colney, Norwich NR4 7UA, UK.
‡Present address: Oxford Nanopore Technologies Ltd, Gosling Building, Edmund Halley Road, Oxford Science Park OX4 4DQ, UK.
§Present address: Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 OES, UK.

**Objectives:** A whole-genome screen at sub-gene resolution was performed to identify candidate loci that contribute to enhanced or diminished ciprofloxacin susceptibility in *Salmonella enterica* serovar Typhi.

**Methods:** A pool of over 1 million transposon insertion mutants of an *S.* Typhi Ty2 derivative were grown in a sub-MIC concentration of ciprofloxacin, or without ciprofloxacin. Transposon-directed insertion site sequencing (TraDIS) identified relative differences between the mutants that grew following the ciprofloxacin treatment compared with the untreated mutant pool, thereby indicating which mutations contribute to gain or loss of ciprofloxacin susceptibility.

**Results:** Approximately 88% of the *S.* Typhi strain's 4895 annotated genes were assayed, and at least 116 were identified as contributing to gain or loss of ciprofloxacin susceptibility. Many of the identified genes are known to influence susceptibility to ciprofloxacin, thereby providing method validation. Genes were identified that were not known previously to be involved in susceptibility, and some of these had no previously known phenotype. Susceptibility to ciprofloxacin was enhanced by insertion mutations in genes coding for efflux, other surface-associated functions, DNA repair and expression regulation, including *phoP*, *barA* and *marA*. Insertion mutations that diminished susceptibility were predominantly in genes coding for surface polysaccharide biosynthesis and regulatory genes, including *slyA*, *emrR*, *envZ* and *cpxR*.

**Conclusions:** A genomics approach has identified novel contributors to gain or loss of ciprofloxacin susceptibility in *S.* Typhi, expanding our understanding of the impact of fluoroquinolones on bacteria and of mechanisms that may contribute to resistance. The data also demonstrate the power of the TraDIS technology for antibacterial research.

## Introduction

*Salmonella enterica* subsp. *enterica* serovar Typhi causes tens of millions of cases of typhoid fever, resulting in over 100 000 deaths annually.[1] These are likely to be underestimates because of the predominance of typhoid fever in low- to middle-income countries where there is often a paucity of diagnostic facilities[2] capable of differentiating typhoid fever from other, clinically similar, febrile diseases.[3] Since the introduction of chloramphenicol for the treatment of typhoid, the spread of antibiotic-resistant *S.* Typhi strains has led to treatment failures.[4] The emergence of MDR strains associated with the acquisition of plasmids[5] and the emergence of the H58 haplotype[6,7] and of XDR strains has led to typhoid fever that

fails to respond to treatment with any of the antibiotics commonly used for treatment, including chloramphenicol, sulfamethoxazole/trimethoprim, ampicillin/amoxicillin, ciprofloxacin and ceftriaxone.[8,9] Furthermore, XDR typhoid fever is now spreading in Pakistan.[10]

Ciprofloxacin (and other fluoroquinolone antibacterials) target the topoisomerase enzymes, DNA gyrase and topoisomerase IV, which are essential functions required for the maintenance of appropriate levels of DNA topology. In *Escherichia coli* and *Salmonella*, resistance is multifactorial, but usually requires point mutations leading to amino acid substitutions at Ser83 of the DNA gyrase GyrA subunit.[11] Alone, such mutations reduce

susceptibility to fluoroquinolones and have resulted in prolonged treatment times with increased shedding, and outright treatment failures.[6,12–15] However, high-level resistance requires further factors, such as additional mutations within the topoisomerase genes, or is associated with those conferring reduced cell permeability and increased antibiotic efflux, or acquisition of a quinolone resistance determinant, such as *qnr*.[8,11,16–18]

It is likely that other mechanisms exist that contribute to fluoroquinolone resistance in *S*. Typhi, which may be relevant to other bacteria, and the application of transposon insertion sequencing technologies, such as transposon-directed insertion site sequencing (TraDIS),[19–22] provides a way to identify these other mechanisms. This involves growing a very large collection of bacterial transposon insertion mutants as a pool under a growth condition of interest. Within the population of mutants, some will show a loss of susceptibility to the condition, and grow more poorly, whilst others will show reduced susceptibility and grow relatively faster. By determining nucleotide sequences from the transposon insertions into the adjacent DNA and comparing them with a reference whole-genome nucleotide sequence, the sequence reads can pinpoint the locations of many transposon insertions in the pool of mutants simultaneously. The number of sequence reads generated at the different sites provides a semi-quantitative measure of the numbers of mutants and, by using at least several hundred thousand transposon mutants, the whole of the non-essential bacterial genome may be assayed down to a resolution of, on average, a few base pairs. Thus, TraDIS can measure changes in the population of the transposon mutants in a condition of interest compared with a standard control.[21]

In this manuscript, we describe the use of TraDIS to assay the *S*. Typhi genome for genes involved in gain or loss of susceptibility to ciprofloxacin in a strain that already harbours a *gyrA* mutation resulting in a GyrA Ser83Phe amino acid substitution and exhibiting reduced susceptibility to fluoroquinolones.[16] Our data identify many of these genes, including those already known and new ones, thus providing clues as to which genes may mutate and contribute to increased clinical resistance. In addition, mutations that lead to a gain of susceptibility indicate that the products of these genes are candidates for the development of antibacterials that may restore susceptibility to ciprofloxacin.

To our knowledge, this is only the second whole-genome screen to investigate the pathways to gain or loss of susceptibility to a fluoroquinolone at this level of genome resolution in bacteria.[23]

## Materials and methods

### S. Typhi transposon mutant library

The transposon mutant library used for this study has been described previously and was estimated to consist of at least 1 million mini-Tn*5* transposon insertion mutants[21] (for more details see the Supplementary data, available at *JAC* Online). The mutant collection exists, and is used, as a single pool split between experimental growth conditions, and the majority of mutants each contain a single transposon insertion in the genome. The parent strain, WT26 pHCM1, possesses a GyrA Ser83Phe substitution conferring reduced susceptibility to fluoroquinolone antibiotics (MIC of ciprofloxacin 0.25 mg/L compared with 0.016 mg/L for the parent strain), and harbours the multiple antibiotic resistance plasmid pHCM1. This strain has attenuating deletion mutations in *aroC*, *aroD* and *htrA*, and requires supplementation of LB broth with 0.004% phenylalanine, 0.004% tryptophan, 0.001% *para*-aminobenzoic acid, 0.001% dihydrobenzoic acid and 0.004% tyrosine ('aro mix') to grow.[16,24–26]

### Passage of the transposon mutant library pool

The *S*. Typhi transposon mutant pool ($1{\times}10^9$ cfu) was grown in 100 mL of LB broth + aro mix, with or without 0.05 mg/L of ciprofloxacin (about $1/5 \times$ MIC)[16] in duplicate. After overnight incubation at 37°C, a second passage of each of the four cultures was prepared similarly and inoculated with 1 mL of the previous respective culture, and again incubated overnight at 37°C, to give growth amounting to a total of about 15 generations. Genomic DNA was extracted from ${\sim}1{\times}10^{10}$ cells from each culture using a genomic DNA extraction buffer kit and Tip-100G columns (QIAGEN).

### TraDIS sequencing and data analysis

Nucleotide sequences were generated from each extracted DNA sample using the modified protocol described previously.[21] This uses a custom oligonucleotide sequencing primer which anneals to the nucleotides of known sequence at the transposon end to generate nucleotide sequence reads from the transposon into the adjacent target DNA for all of the transposon mutants simultaneously. Nucleotide sequence reads (Table S1) were compared with a reference genome nucleotide sequence that combined the sequences of *S*. Typhi Ty2 (accession number AE014613) and plasmid pHCM1 (accession number NC_003384), using the Bio-Tradis software suite[27] installed on CLIMB virtual machine servers.[28] Nucleotide sequence homology between a sequence read and the reference genome locates a transposon insertion site, and the number of sequence reads that locate with that site is a semi-quantitative measure of the copy number of mutants present in the transposon mutant pool.

The mutant site and number of reads were compared with the genome annotation to determine the number of reads that locate within each gene. Comparison of the data of the controls with the ciprofloxacin-treated duplicates using the Bio-Tradis analysis software toolkit gives the ratio of $\log_2$ fold change ($\log_2$FC), $\log_2$ counts per million ($\log_2$CPM) and *P* and *q* values for each gene. The FC refers to the difference in the number of sequence reads that locate with a gene between ciprofloxacin-treated and untreated conditions. Thus, negative values indicate that insertion mutation in that gene results in a gain in ciprofloxacin susceptibility and positive values a loss. These data were filtered for genes that had $\log_2$ FC values $\geq 1.4$ or $\leq -1.4$ (i.e. an increase or decrease of greater than 2.6-fold). CPM refers to the number of reads per gene if the total number of nucleotide sequence reads generated for the sample had been 1 million. Genes with sequence read values of $\log_2$ CPM <2.75 (less than 6) were discarded from the data set. The data sets presented here have at least 13 million associated sequence reads (Table S1). Thus, any gene represented by fewer than 78 reads was excluded from the analysis. The *P* value is the statistical probability of obtaining the result if the gene is not involved in gain or loss of susceptibility to ciprofloxacin, and the *q* value is the *P* value adjusted for the false discovery rate (the proportion of false positives expected from a test). Gene data filtered as above all had *q* values of <0.00002. Genes within this data set are likely to contribute the most to gain or loss of susceptibility to 0.05 mg/L ciprofloxacin and are presented in Tables 1 and 2, but do not necessarily include all candidates. Supplementary data are available with less stringent thresholds ($-1 > \log_2$FC $>1$, *q* < 0.001; Table S2).

### Validation of candidate genes

Many of the candidate genes identified as contributing to gain or loss of susceptibility to ciprofloxacin are confirmed by published reports (see the Results and discussion). To confirm the TraDIS data and validate the

predicted role of some of the candidate genes in *S*. Typhi gain of ciprofloxacin susceptibility, five genes were selected from the list of candidates for directed inactivation. The construction of these mutations was achieved using the suicide vector method described previously.[16] This method involved the use of intermediate constructs and the generation of mutants in independent duplication to confirm that the observed phenotype was due to the constructed mutation and was not due to changes elsewhere in the genome.

### Relative MIC determinations

Determination of relative differences in the MICs of antibiotics between the five constructed mutants and parent strain was performed in 96-well microtitre plates using dilutions of ciprofloxacin, ofloxacin and nalidixic acid in total volumes of 200 μL of LB broth + aro mix (see above). Two-fold concentration increments were used for nalidixic acid, 1.5-fold for ciprofloxacin and increments of 1.2, 1, 0.85, 0.65 and 0.5 mg/L were used for ofloxacin. Bacteria were added to a concentration of about $10^5$ cfu/mL and incubated at 37°C for 18 h. The lowest concentration at which there was no obvious visible growth was taken as the MIC. MICs were determined for two mutants generated independently for each gene under investigation, and three separate MIC determinations were performed, with the modal value being presented.

## Results and discussion

### Application of the TraDIS method to ciprofloxacin susceptibility

Modification of high-throughput sequencing methodology allows the relative numbers of each transposon mutant in a large mutant pool to be determined.[19–22] A pool of at least 1 million *S*. Typhi Ty2 derivative transposon mutants[21] was grown with or without a sub-MIC concentration (0.05 mg/L; about $^1/_5 \times$ MIC) of ciprofloxacin, and the differences in endpoint growth of the mutants between the two conditions were observed. The average distance between different transposon insertion sites is about 10 bp, so the whole genome has been assayed at this level of resolution (Table S1). The output data from these experiments are expressed as the number of sequence reads that have an identical nucleotide sequence to a particular location in the genome. With reference to the *S*. Typhi Ty2 whole-genome annotation, the number of reads that locate within each gene may then be deduced. Whilst most mutants incorporate a single transposon insertion, each gene will, on average, be represented by dozens of different mutants within the mutant pool, and by hundreds to upwards of several tens of thousands of nucleotide sequence reads (see the Materials and methods). Because the assay was performed using a sub-MIC concentration of ciprofloxacin that allowed many of the mutants to grow, the genes identified are those that contribute to a gain or loss of fitness within the mutant pool grown in these conditions.

### Efflux and porin genes involved in ciprofloxacin susceptibility

Those genes identified (Tables 1 and 2) that are already known to be involved in fluoroquinolone susceptibility[11,29–31] serve to validate the TraDIS methodology and confirm that the fitness changes measured correlate with changes to ciprofloxacin susceptibility. For example, the genes coding for the AcrAB–TolC efflux transporter and the outer membrane porin OmpF were identified by our data as being important for *S*. Typhi susceptibility to ciprofloxacin (Tables 1 and 2; Figure 1a), as shown previously.[17,30,32–35]

Another efflux complex in *E. coli*, EmrAB–TolC, confers reduced susceptibility to several toxins,[36] and this efflux complex is negatively regulated by EmrR. Our data indicate that in *S*. Typhi mutation of *emrR* conferred reduced susceptibility to ciprofloxacin (Table 2), as would be expected if *emrAB* became overexpressed due to loss of repression by EmrR. Mutations in *emrA* or *emrB* did not themselves increase susceptibility to ciprofloxacin, suggesting that *emrAB*-dependent efflux does not contribute significantly to loss of ciprofloxacin susceptibility in the presence of other efflux mechanisms. However, when overexpressed as a result of insertions into the *emrR* repressor gene, *emrAB*-dependent efflux does contribute to susceptibility, as has been observed also for *Salmonella enterica* serovar Typhimurium.[37]

In *E. coli*, *emrD* codes for MDR protein D, an efflux transporter with a wide range of structurally distinct substrates.[38] Unexpectedly, in *S*. Typhi, mutations in *emrD* led to a gain in ciprofloxacin susceptibility, a result which was highly statistically significant (Table 2 and Figure 1b). This difference may be specific to *S*. Typhi, or it may reflect the coordinated regulation of multidrug efflux. It has been shown that disruption of efflux systems results in up-regulation of others in response,[39] and it is possible that *emrD* knockout indirectly induces another ciprofloxacin exporter.

### Regulator genes involved in ciprofloxacin susceptibility

In *E. coli* and *S*. Typhimurium, the AcrAB–TolC efflux system and OmpF are regulated by the *marA/soxS/robA* regulon, and, in addition, by *ramA* in *S*. Typhimurium, which is absent from *E. coli*.[40,41] MarA and Rob are positive regulators of the AcrAB–TolC efflux system, and MarA, in addition, is a negative regulator of the outer membrane porin, OmpF.[40] Our data indicated that *marA* and *rob* insertion mutants of *S*. Typhi were more susceptible to ciprofloxacin (Table 1), as expected if the regulation by these genes in *S*. Typhi is similar to that for *E. coli* and *S*. Typhimurium.

Other regulators involved in expression of *acrAB* and *tolC* include *acrR* and *marR*, which were absent from our gene lists. In our data, *acrR* had a $\log_2 FC$ of 1.0 (average 1500 read counts in controls compared with 2800 for ciprofloxacin-treated cultures) and was therefore removed by our criterion of $-1.5 \geq \log_2 FC \geq 1.5$, even though the *q* value for this gene was $7.4 \times 10^{-30}$. Thus, the $\log_2 FC$ limits employed to generate the gene lists of Tables 1 and 2 will miss some genes that may contribute to gain or loss of ciprofloxacin susceptibility, and *acrR* is one such gene (Figure 1), but will provide a more robust list of gene candidates.

For *marR*, there was little difference in the number of nucleotide sequence reads between the ciprofloxacin-treated and untreated growth conditions ($\log_2 FC = 1.0$). However, following growth with ciprofloxacin, there was an observable increase in the number of transposon insertions oriented such that transcription from the transposon kanamycin resistance gene could read through into *marAB* (Figure 1c). The Bio-Tradis software suite generates statistical data based on insertion sites on a gene-by-gene basis and, although the orientation of the insertions is known (from the DNA strand to which the nucleotide sequence reads locate), the software does not use this information. The enrichment of inserts in

**Table 1.** *S.* Typhi transposon insertion mutants displaying enhanced susceptibility to ciprofloxacin[a]

| Higher function | Gene name | Function | Log$_2$FC | q value[b] |
|---|---|---|---|---|
| Membrane/surface associated | *acrA* | acriflavin resistance protein A; AcrAB–TolC efflux | −9.27 | $3.99 \times 10^{-74}$ |
| | *acrB* | acriflavin resistance protein B; AcrAB–TolC efflux | −6.85 | $2.6 \times 10^{-304}$ |
| | *ybhT* | putative exported protein | −3.24 | $9.99 \times 10^{-23}$ |
| | *tolC* | outer membrane protein TolC; AcrAB–TolC efflux | −3.01 | $1.78 \times 10^{-62}$ |
| | *t3146* | putative membrane protein | −2.04 | $2.61 \times 10^{-58}$ |
| | *t2964* | putative membrane protein; conserved | −1.86 | $3.43 \times 10^{-35}$ |
| | *t3276* | putative outer membrane protein; conserved | −1.75 | $4.27 \times 10^{-12}$ |
| | *mrcA* | penicillin-binding protein 1A | −1.60 | $5.3 \times 10^{-49}$ |
| | *plsC* | 1-acyl-glycerol-3-phosphate acyltransferase | −1.57 | $1.03 \times 10^{-8}$ |
| | *t3147* | putative exported protein | −1.50 | $3.08 \times 10^{-19}$ |
| | *fliJ* | flagellar FliJ protein | −1.41 | $5.86 \times 10^{-12}$ |
| | *marB* | multiple antibiotic resistance protein MarB; periplasmic | −1.41 | $5.15 \times 10^{-16}$ |
| Regulators | *phoP* | transcriptional regulatory protein PhoP | −3.00 | $4 \times 10^{-29}$ |
| | *barA* | sensor protein | −2.87 | $2.27 \times 10^{-62}$ |
| | *marA* | multiple antibiotic resistance protein MarA | −2.87 | $7.17 \times 10^{-50}$ |
| | *tyrR* | transcriptional regulatory protein TyrR | −2.86 | $9.74 \times 10^{-58}$ |
| | *sirA* | invasion response-regulator | −2.58 | $7.03 \times 10^{-7}$ |
| | *cysB* | cys regulon transcriptional activator | −2.54 | $3.3 \times 10^{-172}$ |
| | *t3449* | possible LysR-family transcriptional regulatory protein | −2.51 | $5.59 \times 10^{-16}$ |
| | *phoQ* | sensor protein PhoQ | −1.94 | $4.78 \times 10^{-34}$ |
| | *fadR* | fatty acid-fatty acyl responsive DNA-binding protein | −1.55 | $4.87 \times 10^{-11}$ |
| | *rob* | right origin-binding protein | −1.41 | $2.88 \times 10^{-23}$ |
| DNA repair/nucleoid associated | *hupA* | histone-like DNA-binding protein HU-alpha | −3.57 | $2.66 \times 10^{-74}$ |
| | *recN* | DNA repair protein | −3.19 | $1.7 \times 10^{-20}$ |
| | *xseA* | exodeoxyribonuclease large subunit | −3.04 | $5.7 \times 10^{-64}$ |
| | *sbcB* | exodeoxyribonuclease I | −2.32 | $1.79 \times 10^{-85}$ |
| | *t1056* | putative ATP-dependent helicase | −2.24 | $1.33 \times 10^{-52}$ |
| | *hupB* | DNA-binding protein HU-beta | −2.11 | $7.37 \times 10^{-19}$ |
| | *endA* | endonuclease I | −1.76 | $1.37 \times 10^{-31}$ |
| | *recG* | ATP-dependent DNA helicase | −1.69 | $3.17 \times 10^{-8}$ |
| | *uvrD* | DNA helicase II | −1.42 | $9.16 \times 10^{-17}$ |
| Cell division | *nlpI* | lipoprotein; possibly cell division | −3.41 | $3.07 \times 10^{-29}$ |
| | *ftsN* | cell division protein | −1.86 | $1.34 \times 10^{-5}$ |
| | *dedD* | cell division protein | −1.66 | $1.15 \times 10^{-9}$ |
| | *ftsH* | cell division protein | −1.43 | $9.56 \times 10^{-8}$ |
| RNA/RNA processing | *trpS* | tryptophanyl-tRNA synthetase | −2.36 | $8.06 \times 10^{-17}$ |
| | *hfQ* | host factor-I protein | −1.97 | $3.54 \times 10^{-40}$ |
| | *micF* | small RNA regulator of *ompF* expression | −1.87 | $9.39 \times 10^{-7}$ |
| | *pnp* | polynucleotide phosphorylase | −1.59 | $1.05 \times 10^{-10}$ |
| Others | *t2965* | conserved hypothetical protein | −2.73 | $1.08 \times 10^{-21}$ |
| | *t0625* | tRNA-Pro | −2.00 | $5.12 \times 10^{-11}$ |
| | *t0533* | putative aminotransferase | −1.65 | $2.18 \times 10^{-9}$ |
| | *ygdD* | conserved hypothetical protein | −1.52 | $2.45 \times 10^{-7}$ |

[a]Nucleotide sequence reads are generated specifically from transposon insertion sites and therefore precisely identify the site location. Log$_2$FC refers to the difference in nucleotide sequence reads that locate within a gene between a ciprofloxacin-treated and an untreated culture of a pool of at least 1 million mutants. The number of nucleotide sequence reads that locate within a gene reflects the number of insertion mutants that are present for that gene.[19–22] The values are logarithms in base 2, so negative values indicate that the number of representative mutants is less for ciprofloxacin-treated compared with untreated, and that these mutants have an enhanced susceptibility in these growth conditions.
[b]q values indicate the statistical significance of the data and are *P* values adjusted for the false discovery rate.[27]

one orientation adjacent to genes supports the observation that TraDIS can be used to predict impacts of altered gene expression on phenotype.[42]

### Genes involved in DNA binding and repair

Like other fluoroquinolone antibiotics, ciprofloxacin acts by binding to DNA gyrase and topoisomerase IV, and results in DNA strand

**Table 2.** *S.* Typhi mutants displaying diminished susceptibility to ciprofloxacin

| Higher function | Gene name | Function | Log$_2$FC | *q* value |
|---|---|---|---|---|
| Carbohydrate/polysaccharide metabolism | *pfkA* | 6-phosphofructokinase | 2.30 | $1.02 \times 10^{-38}$ |
| | *tviC* | Vi polysaccharide biosynthesis protein, epimerase | 2.16 | $5.5 \times 10^{-198}$ |
| | *rfbE* | CDP-tyvelose-2-epimerase | 2.11 | $8.14 \times 10^{-94}$ |
| | *waaI* | lipopolysaccharide 1,3-galactosyltransferase | 2.01 | $8.1 \times 10^{-106}$ |
| | *rfbU* | putative glycosyl transferase | 1.97 | $1.01 \times 10^{-60}$ |
| | *rfbM* | mannose-1-phosphate guanylyltransferase | 1.97 | $8 \times 10^{-108}$ |
| | *rfbK* | phosphomannomutase | 1.94 | $2.5 \times 10^{-140}$ |
| | *waaJ* | lipopolysaccharide 1,2-glucosyltransferase | 1.85 | $7.27 \times 10^{-84}$ |
| | *galE* | UDP-glucose 4-epimerase | 1.83 | $3.38 \times 10^{-24}$ |
| | *rffM* | probable UDP-N-acetyl-D-mannosaminuronic acid transferase | 1.81 | $1.44 \times 10^{-51}$ |
| | *rffD* | UDP-ManNAc dehydrogenase | 1.75 | $1.99 \times 10^{-51}$ |
| | *rfbI* | putative reductase RfbI | 1.73 | $2.1 \times 10^{-105}$ |
| | *mtlD* | mannitol-1-phosphate dehydrogenase | 1.68 | $2.67 \times 10^{-72}$ |
| | *nagA* | N-acetylglucosamine-6-phosphate deacetylase | 1.68 | $1.82 \times 10^{-13}$ |
| | *waaK* | lipopolysaccharide 1,2-N-acetylglucosaminetransferase | 1.67 | $1.41 \times 10^{-97}$ |
| | *waaL* | O-antigen ligase | 1.61 | $3.88 \times 10^{-77}$ |
| | *wecB* | UDP-N-acetyl-D-glucosamine 2-epimerase | 1.59 | $4.44 \times 10^{-84}$ |
| | *pgi* | glucose-6-phosphate isomerase | 1.50 | $4.76 \times 10^{-77}$ |
| | *rfbS* | paratose synthase | 1.46 | $3.52 \times 10^{-6}$ |
| Regulators | *slyA* | transcriptional regulator of haemolysin E | 3.19 | $2.8 \times 10^{-111}$ |
| | *emrR* | putative transcriptional regulator | 2.86 | $5.9 \times 10^{-183}$ |
| | *envZ* | two-component sensor kinase EnvZ | 2.21 | $7.41 \times 10^{-12}$ |
| | *cpxR* | envelope stress two-component response regulatory protein | 2.09 | $1.48 \times 10^{-57}$ |
| | *t1707* | putative TetR-family regulatory protein | 1.95 | $8.65 \times 10^{-88}$ |
| | *phoU* | phosphate transport system regulatory protein | 1.86 | $6.91 \times 10^{-14}$ |
| | *nadR* | conserved hypothetical transcriptional regulator | 1.75 | $1.3 \times 10^{-114}$ |
| | *yijC* | possible TetR-family transcriptional regulatory protein | 1.58 | $1.89 \times 10^{-33}$ |
| | *cytR* | transcriptional repressor | 1.57 | $2.17 \times 10^{-72}$ |
| | *rseC* | sigma-E factor regulatory protein RseC | 1.53 | $1.81 \times 10^{-26}$ |
| | *crp* | cyclic AMP receptor protein, catabolite gene activator | 1.51 | $2.55 \times 10^{-7}$ |
| | *gntR* | gluconate utilization operon repressor | 1.45 | $3.34 \times 10^{-33}$ |
| | *gatR* | galactitol utilization operon repressor | 1.45 | $1.37 \times 10^{-7}$ |
| | *spf* | small regulatory RNA | 1.45 | $1.81 \times 10^{-11}$ |
| | *mtlR* | mannitol operon repressor | 1.40 | $2 \times 10^{-47}$ |
| Membrane/surface associated | *ompF* | outer membrane protein F precursor | 3.91 | 0 |
| | *t0641* | putative outer membrane lipoprotein | 2.77 | $7.4 \times 10^{-171}$ |
| | *emrD* | multidrug resistance protein D | 2.26 | $2.9 \times 10^{-185}$ |
| | *dgkA* | diacylglycerol kinase | 2.04 | $3.24 \times 10^{-16}$ |
| | *ppk* | polyphosphate kinase | 1.95 | $5.5 \times 10^{-169}$ |
| | *lepB* | signal peptidase I | 1.78 | $9.39 \times 10^{-7}$ |
| | *trkH* | trk system potassium uptake protein | 1.78 | $5.06 \times 10^{-30}$ |
| | *t3816* | putative secreted protein | 1.69 | $3.59 \times 10^{-56}$ |
| | *nucE* | putative secretion protein | 1.57 | $7.26 \times 10^{-7}$ |
| | *yabI* | DedA-family integral membrane protein | 1.54 | $2.16 \times 10^{-25}$ |
| | *yhdA* | putative lipoprotein | 1.54 | $3.09 \times 10^{-64}$ |
| | *t2427* | hypothetical major facilitator family transport protein | 1.47 | $6.28 \times 10^{-48}$ |
| Redox associated | *gor* | glutathione reductase | 2.95 | $6.5 \times 10^{-158}$ |
| | *trxB* | thioredoxin reductase | 1.62 | $8.04 \times 10^{-24}$ |
| | *t1325* | putative NADH reducing dehydrogenase | 1.48 | $1.8 \times 10^{-52}$ |
| | *gshB* | glutathione synthetase | 1.42 | $7.99 \times 10^{-10}$ |
| | *t1326* | putative ferredoxin-like protein, cytoplasmic membrane | 1.41 | $2.27 \times 10^{-17}$ |

*Continued*

**Table 2.** *Continued*

| Higher function | Gene name | Function | Log$_2$FC | $q$ value |
|---|---|---|---|---|
| Nucleoid associated | *parC* | topoisomerase IV subunit A | 1.97 | $5.61 \times 10^{-17}$ |
| | *hns* | DNA-binding protein | 1.51 | $1.14 \times 10^{-84}$ |
| | *hepA* | probable ATP-dependent helicase HepA | 1.50 | $1.72 \times 10^{-70}$ |
| RNA/RNA processing | *rpoC* | DNA-directed RNA polymerase, beta'-subunit | 1.69 | $3.2 \times 10^{-115}$ |
| | *rne* | ribonuclease E | 1.61 | $9.9 \times 10^{-22}$ |
| Murein metabolism | *aspC* | aspartate aminotransferase | 1.74 | $1.62 \times 10^{-5}$ |
| | *dacA* | D-alanine carboxypeptidase | 1.47 | $1.3 \times 10^{-72}$ |
| | *metL* | aspartokinase II | 1.45 | $2.31 \times 10^{-57}$ |
| Others | *t3103* | conserved hypothetical protein | 2.76 | $9.4 \times 10^{-161}$ |
| | *guaA* | GMP synthase | 2.29 | $2.51 \times 10^{-14}$ |
| | *yabC* | conserved hypothetical protein | 2.22 | $2.04 \times 10^{-13}$ |
| | *yojL* | thiamine biosynthesis protein | 1.87 | $1.99 \times 10^{-68}$ |
| | *efp* | elongation factor P | 1.79 | $2.21 \times 10^{-11}$ |
| | *t2640* | conserved hypothetical protein | 1.68 | $1.68 \times 10^{-14}$ |
| | *gidA* | glucose inhibited division protein | 1.68 | $1.84 \times 10^{-9}$ |
| | *thdF* | thiophene and furan oxidation protein | 1.61 | $8.66 \times 10^{-7}$ |
| | *aphA* | class B acid phosphatase precursor | 1.49 | $1.06 \times 10^{-33}$ |
| | *thiS* | thiamine biosynthesis protein | 1.47 | $2.07 \times 10^{-7}$ |
| | *ybeA* | conserved hypothetical protein | 1.44 | $1.83 \times 10^{-10}$ |
| | *ubiB* | flavin reductase | 1.44 | $1.1 \times 10^{-37}$ |
| | *ybeB* | conserved hypothetical protein | 1.42 | $7.29 \times 10^{-19}$ |
| | *yhjJ* | putative zinc-protease precursor | 1.41 | $5.29 \times 10^{-71}$ |

Refer to footnotes for Table 1. Positive values for log$_2$FC indicate that the number of representative mutants for each gene is greater for ciprofloxacin-treated compared with untreated, and that these mutants therefore have diminished ciprofloxacin susceptibility in these growth conditions.

breaks.[43,44] Hence, our whole-genome assay identified a number of genes coding for functions involved in DNA repair, such as *recN*, *recG*, *uvrD* and *xseA* (Table 1), which have been identified previously as contributing to diminished ciprofloxacin susceptibility in *E. coli*.[31] In addition, we identified *hupA* and *hupB*, which encode the HU histone-like protein that binds to DNA recombination and repair intermediates, protecting them from exonuclease degradation.[45] The HU protein is also known to control a regulon encompassing approximately 8% of the *E. coli* genome[46] and may contribute to loss of ciprofloxacin susceptibility via several indirect regulatory mechanisms.

### Transposon insertions adjacent to genes coding for the fluoroquinolone target proteins and RNA polymerase genes

The ciprofloxacin targets, DNA gyrase and topoisomerase IV enzymes, act to maintain DNA topology in the bacterial genome, and their encoding genes (*gyrA* and *gyrB* for DNA gyrase, and *parC* and *parE* for topoisomerase IV) are essential.[21,42,47] Consequently, transposon mutants of these genes are non-viable and are absent from our transposon mutant library, with the result that few or no sequence reads were identical to the nucleotide sequences of these genes. As a result, the *gyrA*, *gyrB* and *parE* genes were among the 12% of genes that were not assayed. However, there was a significant increase in mutants with insertions in the *parC* gene, indicating that these mutants displayed reduced susceptibility to ciprofloxacin. However, these insertion mutations were within the last 6 bp of *parC* and were oriented such that the transposon kanamycin resistance gene is reverse transcribed into *parC* (Figure 1d). Transposon insertions this close to the end of the *parC* gene probably do not result in inactivation, but may confer some loss in susceptibility to ciprofloxacin due to altered expression of *parC*, such as may occur through post-transcriptional gene silencing by RNA interference resulting from transcription of *parC* in the reverse direction.[48]

Gene *t3103* is known only as being conserved and hypothetical, but mutant numbers for this gene increased relatively in ciprofloxacin-treated cultures (Table 2). The *t3103* gene is upstream of the *parE* gene, and these insertion mutations may manifest their phenotype, at least in part, by modulating *parE* expression rather than being a direct result of insertion into the *t3103* gene (Figure 1e).

For the *rpoC* gene, encoding the essential RNA polymerase β'-subunit, as demonstrated by the absence of insertions across most of the gene (Figure 1f), the number of mutants increased relatively in the ciprofloxacin-treated cultures (Table 2). These insertion mutations were within the last 45 bp of the 3' end of the *rpoC* gene (Figure 1f). Insertions in this part of the gene are unlikely to result in its inactivation, but probably manifest their phenotype through alteration of *rpoC* expression. There is also an increase in mutants with insertion 5' to the *rpoB* gene (Figure 1f), indicating that these mutants, which probably alter transcription of the *rpoBC* gene, also display diminished ciprofloxacin susceptibility. RNA polymerase mutants have been shown previously to influence ciprofloxacin susceptibility

**Figure 1.** Mutant changes across some genetic locations following growth supplemented with ciprofloxacin. Distribution of nucleotide sequence reads generated by TraDIS at six different *S.* Typhi genetic loci following growth supplemented with and without ciprofloxacin, viewed using Artemis.[56] At the bottom of each panel, genetic maps indicate the positions of the genes coded by the forward (dark grey) or reverse (light grey) DNA strands. Above each genetic map are four location and quantification plots, one for each duplicate experiment treated with ciprofloxacin (CIP1 and CIP2) or untreated (control1 and control2). Duplicates indicate the experimental reproducibility. Within the plots, fine vertical bars indicate the location of transposon insertion sites, with the length of the bar proportional to the number of nucleotide sequence reads (and therefore the relative number of mutants) that locate with that insertion site. Bars extending above the central axis indicate transposon insertion mutations oriented such that the kanamycin resistance determinant encoded by the transposon is transcribed in the left to right direction, and those below indicate the reverse orientation. (a) Transposon insertions within the *acrAB* genes coding for efflux are lost in the presence of ciprofloxacin, whilst mutants with insertions in the *acrR* gene, which codes for a repressor of *acrAB*, increase in numbers (log$_2$FC = 1, i.e. by 2-fold). (b) Increased transposon mutants for the EmrD efflux system following growth in the presence of ciprofloxacin. (c) Increased insertion mutants in the *marA* repressor, *marR*, following growth with ciprofloxacin, oriented in the reverse direction such that transcriptional readthrough from the transposon will be into the *marA* gene; also reduced mutants in *marB*. (d) Insertions within the last codon of *parC* increase in the presence of ciprofloxacin, as indicated by an increase in the height of the bar extended above the central axis at this location. These insertions are oriented such that the transposon kanamycin resistance gene may reverse transcribe into the *parC* gene and thereby modulate expression through RNA interference. The bar extended below the central axis in this location is immediately outside of the *parC* gene. (e) Increased transposon insertions within the *t3103* gene with ciprofloxacin treatment may lead to altered expression of the *parE* gene coding for a subunit of topoisomerase IV, which is the secondary target of ciprofloxacin. (f) Transposon insertions into the last 25 bp of the *rpoC*, as well as immediately upstream of both *rpoB* and *rpoC*, increase with ciprofloxacin, suggesting that altered expression of DNA polymerase may play a role in susceptibility.

by increasing MdtK-dependent efflux,[49] and our data suggest that a subtle change in susceptibility may be achieved by modulation of RNA polymerase expression.

### Surface polysaccharide biosynthesis genes involved in ciprofloxacin susceptibility

Our experiments also identified at least 19 genes involved in polysaccharide and/or carbohydrate metabolism, in which transposon insertions reduced ciprofloxacin susceptibility (Table 2). Fifteen of these are involved in surface polysaccharide biosynthesis, including the *waa* (formerly *rfa*) genes *I, J, K* and *waaL*, coding for biosynthesis of the LPS outer core, and the LPS O-antigen biosynthetic genes *rfbE, I, K, M, S* and *rfbU*. Also included were the *galE* gene involved in UDP-galactose synthesis required both for LPS outer core and O-antigen. Other genes included those involved in the biosynthesis of enterobacterial common antigen (ECA), *rffM, rffD* and *wecB*,[50] and *tviC* required for Vi-antigen biosynthesis.[51] There

**Table 3.** MICs of ciprofloxacin (CIP), ofloxacin (OFX) and nalidixic acid (NAL) for defined mutants of *S.* Typhi

| Strain | MIC (mg/L) | | |
| --- | --- | --- | --- |
| | CIP | OFX | NAL |
| WT26 | 0.2 | 1.0 | 256 |
| Δ*xseA* | 0.1 | 0.85 | 128 |
| Δ*phoP* | 0.15 | 0.65 | 128 |
| Δ*hupA* | 0.15 | 0.65 | 128 |
| Δ*tyrR* | 0.15 | 0.85 | 256 |
| Δ*uvrD* | 0.15 | 0.65 | 128 |

For Δ*xseA*, Δ*phoP* and Δ*hupA* mutations, two mutants were generated independently and tested.

are previous reports of LPS mutations resulting in changed susceptibility to fluoroquinolones, but our data provide a more comprehensive set of genes, and are the first to suggest a role for ECA and Vi-antigen.[17,30,34,52]

### Construction of mutants to validate candidate genes involved in diminished ciprofloxacin susceptibility

To confirm the validity of predictions from the TraDIS data, deletion mutations were constructed in the *S.* Typhi WT26 parent strain for the *hupA*, *tyrR*, *phoP*, *uvrD* and *xseA* genes, identified as candidates involved in ciprofloxacin susceptibility. All mutants showed a reduced MIC of ciprofloxacin, though the changes were small (Table 3). The mutants also showed a very small reduction in the MIC of the fluoroquinolone, ofloxacin, and the naphthyridone, nalidixic acid, which acts on GyrA in a similar way to the fluoroquinolones (Table 3). Both *uvrD* and *xseA* have been identified previously as being involved in ciprofloxacin susceptibility in *E. coli*.[31]

These results complement previous reports validating the TraDIS data and demonstrate their sensitivity for identifying loci involved in antibiotic susceptibility and other stressors. Whilst the phenotypic changes observed were small, these were for insertional inactivation mutations, and greater phenotypic changes may result from different types, or combinations, of mutation at these same loci.

### None of the pHCM1-encoded genes contributed to ciprofloxacin susceptibility

Many MDR strains of *S.* Typhi circulating in Southeast Asia harbour plasmid pHCM1 or similar derivatives.[25,26] Thus, this plasmid was transferred into our *S.* Typhi Ty2-derived strain for TraDIS analysis experiments by conjugation. Plasmid pHCM1 is 218 kb and has 251 annotated genes, and our data indicate that none of these pHCM1-encoded genes contributes significantly to ciprofloxacin susceptibility.

### Concluding remarks

The continuing evolution of antibiotic resistance in clinically important human pathogens reduces treatment options for clinicians. A better understanding of the mechanisms of antibiotic resistance may provide opportunities for the identification of agents and implementation of practices to counter resistance, and it may also enable the prediction of when and where resistance will arise.[53]

By combining a very large transposon mutant library with a modified protocol for high-throughput nucleotide sequencing,[21] we have screened about 88% of the genes in the genome of an *S.* Typhi Ty2 derivative for a role in the gain or loss of susceptibility to ciprofloxacin. However, most essential genes in which transposon insertions are not tolerated have not been assayed including, for example, *recA*, which is essential in *S.* Typhi but may also contribute to fluoroquinolone susceptibility.[21,54] Whilst we have identified these genes by using insertional inactivation mutation, and, in the cases that we tested, MIC changes were small (Table 3), it is logical to consider that other types of mutations (for example, base or expression changes) in these same genes could also enhance or diminish the phenotype to a greater or lesser extent. Thus, using a whole-genome screen, we have found simultaneously many of the fluoroquinolone susceptibility mechanisms that have taken the previous decades to identify for *E. coli* and *Salmonella*, and new mechanisms, including those associated with genes of previously unknown function and phenotype, thus providing the first clues to their roles in bacterial biology.

## Transparency declarations

None to declare.

## Supplementary data

Supplementary data, including Tables S1 and S2, are available at *JAC* Online.

## References

**1** Stanaway JD, Reiner RC, Blacker BF *et al.* The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Infect Dis* 2019; **19**: 369–81.

**2** Wain J, Hendriksen R, Mikoleit M *et al.* Typhoid fever. *Lancet* 2015; **385**: 1136–45.

**3** Mogasale V, Mogasale V, Ramani E *et al.* Revisiting typhoid fever surveillance in low and middle income countries: lessons from systematic

literature review of population-based longitudinal studies. *BMC Infect Dis* 2016; **16**: 35.

**4** Wain J, Kidgell C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. *Trans R Soc Trop Med Hyg* 2004; **98**: 423–30.

**5** Phan M, Wain J. IncHI plasmids, a dynamic link between resistance and pathogenicity. *J Infect Dev Ctries* 2008; **2**: 272–8.

**6** Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. *Clin Infect Dis* 2010; **50**: 241–6.

**7** Wong VK, Baker S, Pickard DJ *et al*. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of *Salmonella* Typhi identifies inter- and intracontinental transmission events. *Nat Genet* 2015; **47**: 632–9.

**8** Klemm EJ, Shakoor S, Page AJ *et al*. Emergence of an extensively drug-resistant *Salmonella enterica* serovar typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. *mBio* 2018; **9**: e00105–18.

**9** Yousafzai M, Qamar F, Shakoor S *et al*. Ceftriaxone-resistant *Salmonella* Typhi outbreak in Hyderabad City of Sindh, Pakistan: high time for the introduction of typhoid conjugate vaccine. *Clin Infect Dis* 2019; **68** Suppl 1: S16–21.

**10** Rasheed F, Saeed M, Alikhan N-F *et al*. Emergence of resistance to fluoroquinolones and third-generation cephalosporins in *Salmonella* Typhi in Lahore, Pakistan. *medRxiv* 2020; doi:10.1101/2020.02.12.20020578.

**11** Redgrave L, Sutton S, Webber M *et al*. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. *Trends Microbiol* 2014; **22**: 438–45.

**12** Wain J, Hoa NT, Chinh NT *et al*. Quinolone-resistant *Salmonella typhi* in Viet Nam: molecular basis of resistance and clinical response to treatment. *Clin Infect Dis* 1997; **25**: 1404–10.

**13** Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant *Salmonella typhi*: a worldwide epidemic. *Clin Infect Dis* 1997; **24** Suppl 1: S106–9.

**14** Cooke F, Wain J. The emergence of antibiotic resistance in typhoid fever. *Travel Med Infect Dis* 2004; **2**: 67–74.

**15** Thompson CN, Karkey A, Dongol S *et al*. Treatment response in enteric fever in an era of increasing antimicrobial resistance: an individual patient data analysis of 2092 participants enrolled into 4 randomized, controlled trials in Nepal. *Clin Infect Dis* 2017; **64**: 1522–31.

**16** Turner AK, Nair S, Wain J. The acquisition of full fluoroquinolone resistance in *Salmonella* Typhi by accumulation of point mutations in the topoisomerase targets. *J Antimicrob Chemother* 2006; **58**: 733–40.

**17** Everett MJ, Jin YF, Ricci V *et al*. Contributions of individual mechanisms to fluoroquinolone resistance in 36 *Escherichia coli* strains isolated from humans and animals. *Antimicrob Agents Chemother* 1996; **40**: 2380–6.

**18** Morgan-Linnell SK, Zechiedrich L. Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in *Escherichia coli*. *Antimicrob Agents Chemother* 2007; **51**: 4205–8.

**19** Gawronski JD, Wong SMS, Giannoukos G *et al*. Tracking insertion mutants within libraries by deep sequencing and a genome-wide screen for *Haemophilus* genes required in the lung. *Proc Natl Acad Sci USA* 2009; **106**: 16422–7.

**20** Goodman AL, McNulty NP, Zhao Y *et al*. Identifying genetic determinants needed to establish a human gut symbiont in its habitat. *Cell Host Microbe* 2009; **6**: 279–89.

**21** Langridge GC, Phan M-D, Turner DJ *et al*. Simultaneous assay of every *Salmonella* Typhi gene using one million transposon mutants. *Genome Res* 2009; **19**: 2308–16.

**22** van Opijnen T, Bodi KL, Camilli A. Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms. *Nat Methods* 2009; **6**: 767–72.

**23** Jana B, Cain AK, Doerrler WT *et al*. The secondary resistome of multidrug-resistant *Klebsiella pneumoniae*. *Sci Rep* 2017; **7**: 42483.

**24** Tacket CO, Sztein MB, Wasserman SS *et al*. Phase 2 clinical trial of attenuated *Salmonella enterica* serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. *Infect Immun* 2000; **68**: 1196–201.

**25** Holt KE, Phan MD, Baker S *et al*. Emergence of a globally dominant IncHI1 plasmid type associated with multiple drug resistant typhoid. *PLoS Negl Trop Dis* 2011; **5**: 19.

**26** Phan M, Kidgell C, Nair S *et al*. Variation in *Salmonella enterica* serovar typhi IncHI1 plasmids during the global spread of resistant typhoid fever. *Antimicrob Agents Chemother* 2009; **53**: 716–27.

**27** Barquist L, Mayho M, Cummins C *et al*. The TraDIS toolkit: sequencing and analysis for dense transposon mutant libraries. *Bioinformatics* 2016; **32**: 1109–11.

**28** Connor TR, Loman NJ, Thompson S *et al*. CLIMB (the Cloud Infrastructure for Microbial Bioinformatics): an online resource for the medical microbiology community. *Microb Genom* 2016; **2**: e000086.

**29** Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. *Cold Spring Harb Perspect Med* 2016; **6**: a025320.

**30** Vinué L, Hooper DC, Jacoby GA. Chromosomal mutations that accompany *qnr* in clinical isolates of *Escherichia coli*. *Int J Antimicrobial Agents* 2018; **51**: 479–83.

**31** Liu A, Tran L, Becket E *et al*. Antibiotic sensitivity profiles determined with an *Escherichia coli* gene knockout collection: generating an antibiotic bar code. *Antimicrob Agents Chemother* 2010; **54**: 1393–403.

**32** Huguet A, Pensec J, Soumet C. Resistance in *Escherichia coli*: variable contribution of efflux pumps with respect to different fluoroquinolones. *J Appl Microbiol* 2013; **114**: 1294–9.

**33** Delcour AH. Outer membrane permeability and antibiotic resistance. *Biochim Biophys Acta* 2009; **5**: 808–16.

**34** Chenia HY, Pillay B, Pillay D. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. *J Antimicrob Chemother* 2006; **58**: 1274–8.

**35** Giraud E, Cloeckaert A, Kerboeuf D *et al*. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in *Salmonella enterica* serovar typhimurium. *Antimicrob Agents Chemother* 2000; **44**: 1223–8.

**36** Lomovskaya O, Lewis K, Matin A. EmrR is a negative regulator of the *Escherichia coli* multidrug resistance pump EmrAB. *J Bacteriol* **177**: 2328–34.

**37** Chen S, Cui S, McDermott PF *et al*. Contribution of target gene mutations and efflux to decreased susceptibility of *Salmonella enterica* serovar typhimurium to fluoroquinolones and other antimicrobials. *Antimicrob Agents Chemother* 2007; **51**: 535–42.

**38** Yin Y, He X, Szewczyk P *et al*. Structure of the multidrug transporter EmrD from *Escherichia coli*. *Science* 2006; **312**: 741–4.

**39** Zhang C-Z, Chen P-X, Yang L *et al*. Coordinated expression of acrAB–tolC and eight other functional efflux pumps through activating ramA and marA in *Salmonella enterica* serovar Typhimurium. *Microb Drug Resist* 2018; **24**: 120–5.

**40** Duval V, Lister IM. MarA, SoxS and Rob of *Escherichia coli*—global regulators of multidrug resistance, virulence and stress response. *Int J Biotechnol Wellness Ind* 2013; **2**: 101–24.

**41** Weston N, Sharma P, Ricci V *et al*. Regulation of the AcrAB–TolC efflux pump in Enterobacteriaceae. *Res Microbiol* 2017; **169**: 425–31.

**42** Goodall ECA, Robinson A, Johnston IG *et al*. The essential genome of *Escherichia coli* K-12. *mBio* 2018; **9**: e02096–17.

**43** Correia S, Poeta P, Hebraud M *et al*. Mechanisms of quinolone action and resistance: where do we stand? *J Med Microbiol* 2017; **66**: 551–9.

**44** Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. *Biochemistry* 2014; **53**: 1565–74.

**45** Kamashev D, Rouviere-Yaniv J. The histone-like protein HU binds specifically to DNA recombination and repair intermediates. *EMBO J* 2000; **19**: 6527–35.

**46** Oberto J, Nabti S, Jooste V *et al.* The HU regulon is composed of genes responding to anaerobiosis, acid stress, high osmolarity and SOS induction. *PLoS One* 2009; **4**: e4367.

**47** Baba T, Ara T, Hasegawa M *et al.* Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol Syst Biol* 2006; **2**: 2006.0008.

**48** Bass BL. Double-stranded RNA as a template for gene silencing. *Cell* 2000; **101**: 235–8.

**49** Pietsch F, Bergman JM, Brandis G *et al.* Ciprofloxacin selects for RNA polymerase mutations with pleiotropic antibiotic resistance effects. *J Antimicrob Chemother* 2017; **72**: 75–84.

**50** Rick PD, Silver RP, Enterobacterial common antigen and capsular polysaccharides. In: FC Neidhardt, ed. *Escherichia coli and Salmonella: Molecular and Cellular Biology*, 2nd edn. ASM Press, 1996: 104–122.

**51** Zhang H, Zhou Y, Bao H *et al.* Vi antigen biosynthesis in *Salmonella typhi*: characterization of UDP-N-acetylglucosamine C-6 dehydrogenase (TviB) and UDP-N-acetylglucosaminuronic acid C-4 epimerase (TviC). *Biochemistry* 2006; **45**: 8163–73.

**52** Hirai K, Aoyama H, Irikura T *et al.* Differences in susceptibility to quinolones of outer membrane mutants of *Salmonella typhimurium* and *Escherichia coli*. *Antimicrob Agents Chemother* 1986; **29**: 535–8.

**53** Martínez JL, Baquero F, Andersson DI. Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics. *Curr Opin Pharmacol* 2011; **11**: 439–45.

**54** Qin T-T, Kang H-Q, Ma P *et al.* SOS response and its regulation on the fluoroquinolone resistance. *Ann Transl Med* 2015; **3**: 358.

**55** Keseler IM, Mackie A, Santos-Zavaleta A *et al.* The EcoCyc database: reflecting new knowledge about *Escherichia coli* K-12. *Nucleic Acids Res* 2016; **45**: D543–50.

**56** Carver T, Harris SR, Berriman M *et al.* Artemis: an integrated platform for visualization and analysis of high-throughput sequence-based experimental data. *Bioinformatics* 2012; **28**: 464–9.